Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients:
updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study
Authors
W Eberhardt
1
Universitätsklinikum Essen, Ruhrlandklinik, West German Cancer Center, Universität
Duisburg-Essen
MC Garassino
2
Fondazione Irccs Istituto Nazionale Dei Tumori, Thoracic Oncology Unit
NA Rizvi
3
New York-Presbyterian/Columbia University Medical Center
B Besse
4
Gustave Roussy, Villejuif France and Paris Sud University
PA Jänne
5
Dana-Farber Cancer Institute
S Peters
6
Hfr Fribourg-Hôpital Cantonal
C Keong Toh
7
National Cancer Centre
T Kurata
8
Kansai Medical University Hirakata Hospital
E Carcereny Costa
9
Catalan Institute of Oncology Badalona – Germans Trias I Pujol Hospital Badalona
